Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that the companies have agreed ...
New service leverages speech recognition and generative AI to automatically create preliminary clinical documentation from patient-clinician conversations ...
India based biopharmaceutical firm Bharat Serums and Vaccines has roped in Bureau Veritas (India) Pvt. Ltd. (BVIL), a world leader in Audit and Certificati...
The FDA clearance also includes the company's core technology platform, the proprietary AXINON® System, that incorporates diagnostic testing algor...
As artificial intelligence (AI) and machine learning is commoditized, data becomes an enterprise's competitive advantage. Accessing high-quality data is ex...
What if there was a solution? A golden key or antidote to lift the fog and restore your mind? How far would you go to obtain it? And if it doesn't ...
LEED is a globally recognized symbol of sustainability achievement and leadership, and is a key milestone for AES, enabling it to meet increased customer d...
The initiative combines Proscia’s innovative digital pathology software platform Concentriq Dx and Leica Biosystems’ scanner hardware. Proscia&...
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't k...
To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helpi...
Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce the results of a recent sc...
Inizio Engage is pleased to announce the launch of Patient Access Services. This custom-built, integrated suite of patient support ser...
Agilent Technologies Inc. (NYSE: A) announced the launch of new Gen6 software for all Agilent BioTek detection instruments. Featuring a broad range o...
U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) ‘combination patent’ to be invalid Novartis wi...
© 2024 Biopharma Boardroom. All Rights Reserved.
